

DATA MANAGERS AND CLINICAL RESEARCH PROFESSIONALS

Session Type and Date	Session Title and Description
Plenary 3 (Thurs 2/20)	<p>Alternative Donor Transplant</p> <p>In this session we will focus on the use of alternative donors for allogeneic transplantation. We will discuss the pros and cons of mismatched unrelated, haploidentical and cord blood transplants. We will recognize the clinical challenges in these different fields and strategies instituted by transplant centers to improve clinical outcomes. We will review the early days, current advantages and challenges, and finally promising efforts to further strengthen their role as a highly desired stem cell sources in patients undergoing hematopoietic stem cell transplantation.</p>
Concurrent 5 (Thurs 2/20)	<p>Infection after Transplant</p> <p>Infection remains a leading cause of non-relapse related mortality. New approaches to preventing and treating infection are needed. This session describes the contemporary landscape in occurrence and types of infection after HCT. How data relating to the individual's genetics, microbiome, resistome, and immune responses might be used to better characterize risk for infection will be discussed. The role of cellular therapies for prevention and treatment of serious infection will also be discussed.</p>
Plenary 4 (Fri 2/21)	<p>ASTCT President's Symposium: Personalizing Survivorship Care in Transplant and Cell Therapy</p> <p>Late complications are a well-recognized sequelae of hematopoietic cell transplantation. Research has led to better understanding of the pathogenesis, risk factors, prevention and management of late effects. Many principles of post-transplant survivorship care can be applied to the nascent field of cell therapy. This session will review recent advances in transplantation late effects. Presentations will focus on current knowledge about biology of late complications following transplantation, the use of health technology tools to personalize survivorship care and facilitate self-management in transplant recipients, and the role of patient reported outcomes in research and clinical care. Speakers will also provide examples of the application of these aspects of survivorship towards recipients of cellular therapies.</p>
Concurrent 8 (Sat 2/22)	<p>Advances in Microbiome on Transplant and Cellular Therapy Outcomes</p> <p>Microbial communities in the body can have a profound impact on outcomes after transplant and immunotherapy. Speaker in this session will describe changes in gut microbial communities after hematopoietic cell transplantation and how these are linked to graft-versus-host disease, with an exploration of potential mechanisms involved in pathogenesis and a discussion of strategies to retain beneficial microbes in patients undergoing transplantation. We will also explore the connections between the microbiome and the immune response in patients with cancer, and how this is relevant in transplantation and cancer therapy including immunotherapy. Finally, we will describe strategies for altering the microbiota of patients undergoing cancer therapy with the goal of improving anti-tumor responses, reducing infections, and modulating immunity. The safety and efficacy of fecal microbiota transplantation in immunocompromised patients will be described, and the potential of newly emerging microbial therapeutics will be highlighted.</p>
Plenary 6 (Sun 2/23)	<p>ASTCT/CIBMTR/EBMT Joint Session: Bridging the gap in BMT and cellular therapy between North America and Europe</p> <p>This joint session organized by the ASTCT, the CIBMTR and the EBMT will review areas of strength and successful collaborations in blood and marrow transplantation and cellular therapy between North America and Europe, and will lay the foundation for future collaborative work in this area. First topic in this session will highlight differences and similarities in transplantation practices in the two geographical areas, describe their rationale and impact on patient outcomes, and identify areas where best practices could potentially be translated across countries and continents. A second topic will review the current landscape and penetration of CAR-T cell therapies in North America and Europe and will discuss challenges faced in the areas of clinical trials, commercial implementation and regulatory issues. This topic will also include discussion of successful practices and policies that countries in the process of starting CAR-T cell therapies can consider, including their economic aspects and costs. The last speaker in this session will highlight areas of successful collaboration in registry research and clinical trials between North America and Europe in blood and marrow transplantation and cellular therapy. This topic will also include discussion of opportunities for enhancing collaborative research in this area between the two continents.</p>